logo

For the Inventor, By the Inventor

Berkeley, CA, United States of America

Dynavax Technologies Corporation


USPTO Granted Patents = 66

% Expired Patents = 36.4



Trademarks = 14

Forward Citations = 998

Loading Chart...
Loading Chart...

55 inventors (with patents filed for the assignee):

goldMedal Robert L Coffman (23 out of 29 patents)

silverMedal Karen L Fearon (21 out of 26 patents)

bronzeMedal Dino Dina (19 out of 38 patents)

4.  Stephen F Tuck (19 out of 19 patents)

5.  Gary Van Nest (13 out of 23 patents)

6.  Cristiana Guiducci (11 out of 12 patents)

7.  Franck J Barrat (8 out of 11 patents)

8.  Radwan Kiwan (7 out of 9 patents)

9.  Jason Marshall (5 out of 6 patents)

10.  Robert S Janssen (5 out of 6 patents)

11.  Stewart D Chipman (4 out of 6 patents)

12.  Gary S Ott (4 out of 23 patents)

13.  David Novack (4 out of 4 patents)

14.  Albert Frederick Candia, Iii (3 out of 3 patents)

15.  Richard Thomas Beresis (3 out of 6 patents)


Core Competencies:
Vaccines
Toll-Like Receptors
Immunogenicity
CpG-Adjuvanted
Immunostimulatory Oligonucleotides
Chimeric Compounds
Inhibitory Oligonucleotides
Biodegradable Formulations
Cancer Treatment
SARS-CoV-2
Autoimmunity
Hepatitis B

66 patents:

1. 12605442 - Production of vaccines comprising inactivated SARS-CoV-2 viral particles (2026-04-21),
2. 12569553 - SHINGLES VACCINES COMPRISING A TLR9 AGONIST (2026-03-10),
3. 12378255 - Toll-like receptor antagonist compounds and methods of use (2025-08-05),
4. 12364745 - Immunogenicity of a CpG-adjuvanted recombinant plague vaccine (2025-07-22),
5. 12296002 - Immunogenic composition against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (2025-05-13),
6. 11981670 - Alkyl chain modified imidazoquinoline TLR7/8 agonist compounds and uses thereof (2024-05-14),
7. 11827641 - Toll-like receptor antagonist compounds and methods of use (2023-11-28),
8. 11684669 - CpG-adjuvanted SARS-CoV-2 virus vaccine (2023-06-27),
9. 11370794 - Toll-like receptor antagonist compounds and methods of use (2022-06-28),
10. 11124510 - Alkyl chain modified imidazoquinoline TLR7/8 agonist compounds and uses thereof (2021-09-21),
11. 10751412 - Combination of a PD-1 antagonist and CPG-C type oligonucleotide for treating cancer (2020-08-25),
12. 10722591 - Cleavable conjugates of TLR7/8 agonist compounds, methods for preparation, and uses thereof (2020-07-28),
13. 10618896 - Alkyl chain modified imidazoquinoline TLR7/8 agonist compounds and uses thereof (2020-04-14),
14. 10548975 - Branched chimeric compounds, and methods of use thereof (2020-02-04),
15. 10369168 - Administration of polynucleotide toll-like receptor 9 agonists for treating cancer (2019-08-06),
Dynavax Technologies Corporation is a biopharmaceutical company focused on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. The company's proprietary TLR platform is utilized in various vaccine and immuno-oncology programs. Dynavax's goal is to provide innovative and effective solutions to prevent and treat diseases, with a primary focus on infectious diseases and cancer.
This text is generated by artificial intelligence and may not be accurate.

logo

Company Badge

USPTO Data Jan 1 1976 - Sep 15 2026

66 Patents

#8 in Berkeley, CA

#1,286 in California

#5,516 in US

#11,140 in the World

Berkeley, CA (US)
Berkeley, CA, United States of America

Dynavax Technologies Corporation

Forward Citations = 998

55 inventors:

goldMedal Robert L Coffman (23 out of 29 patents)

silverMedal Karen L Fearon (21 out of 26 patents)

bronzeMedal Dino Dina (19 out of 38 patents)

4.  Stephen F Tuck (19 out of 19 patents)

5.  Gary Van Nest (13 out of 23 patents)

Please report any incorrect information to [email protected]
Loading…